TREM1 and neoplasm: To evaluate the extent to which the 16-gene TREM1 myeloid signature was tumor-specific, we merged the myeloid populations from BCC tumors with existing scRNA-Seq datasets from healthy individuals, individuals with a variety of inflammatory skin diseases, and patients with different types of cancer29–32.